Vanda Pharmaceuticals (VNDA) Intangibles (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Intangibles data on file, last reported at $115.1 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles rose 2.45% year-over-year to $115.1 million; the trailing twelve-month figure through Mar 2026 stood at $115.1 million (up 2.45% YoY), and the FY2025 full-year result was $117.1 million, up 2.62% from the prior year.
• Intangibles eased to $115.1 million in Q1 2026, from $117.1 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $121.4 million in Q4 2023 to a low of $17.4 million in Q3 2023.
• A 5-year average of $75.4 million and a median of $110.6 million in 2025 frame the typical range for Intangibles.
• Across the five-year window, Intangibles dropped 8.0% in 2023 and surged 564.72% in 2024, its largest moves.
• Tracing VNDA's Intangibles over 5 years: stood at $18.6 million in 2022, then surged by 553.75% to $121.4 million in 2023, then dropped by 5.99% to $114.1 million in 2024, then increased by 2.62% to $117.1 million in 2025, then decreased by 1.7% to $115.1 million in 2026.
• Business Quant data shows VNDA's Intangibles at $115.1 million in Q1 2026, $117.1 million in Q4 2025, and $108.8 million in Q3 2025.